Creutzfeldt-Jakob disease future or investigational therapies
|
Creutzfeldt-Jakob disease Microchapters |
|
Differentiating Creutzfeldt-Jakob disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Creutzfeldt-Jakob disease future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Creutzfeldt-Jakob disease future or investigational therapies |
|
FDA on Creutzfeldt-Jakob disease future or investigational therapies |
|
CDC on Creutzfeldt-Jakob disease future or investigational therapies |
|
Creutzfeldt-Jakob disease future or investigational therapies in the news |
|
Blogs on Creutzfeldt-Jakob disease future or investigational therapies |
|
Risk calculators and risk factors for Creutzfeldt-Jakob disease future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Future or Investigational Therapies
As of 2007, there is no cure for CJD, a fatal disease, and the search for viable treatments continues. An experimental treatment was given to a northern irish teenager, Jonathan Simms, in January 2003.[1] The medication, called pentosan polysulphate (PPS) which is used to treat interstitial cystitis, was infused into the patient's lateral ventricle within the brain. PPS did not seem to stop the disease from progressing. However, the treatment is alleged to slow the progression of the otherwise untreatable disease, and may have contributed to the longer than expected survival of the seven patients that were studied.[2] The CJD Therapy Advisory Group to the UK Health Departments advises that data are not sufficient to support claims that pentosan polysulphate is an effective treatment and suggests that further research in animal models is appropriate.[3] A 2007 review of the treatment of 26 patients with PPS finds no proof of efficacy because of the lack of accepted objective criteria.[4]
Scientists have investigated using RNA interference to slow the progression of scrapie in mice. The RNA blocks production of the protein that the CJD process transforms into prions. This research is unlikely to lead to a human therapy for many years.[5] In 2013 Karapetyan et al reported that astemizole, a medication which has already been approved for human use, has been found to have anti-prion activity and may lead to a treatment for Creutzfeldt-Jakob disease.[6]
References
- ↑ "Teenager with vCJD 'stable". BBC News. 13 December2004. Retrieved 2007-01-01. Check date values in:
|date=(help) - ↑ Bone, Ian (12 July 2006). "Intraventricular Pentosan Polysulphate in Human Prion Diseases: A study of Experience in the United Kingdom". Medical Research Council. Retrieved 2007-01-01. Check date values in:
|date=(help) - ↑ "Use of Pentosan Polysulphate in the treatment of, or prevention of, vCJD". Department of Health:CJD Therapy Advisory Group. Retrieved 2007-10-30.
- ↑ Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A, Doh-Ura K (2007). "Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?". Expert opinion on biological therapy. 7 (5): 713–26. doi:10.1517/14712598.7.5.713. PMID 17477808.
- ↑ "Revamp of brain 'could slow CJD'". BBC News. 4 December 2006. Retrieved 2007-01-01. Check date values in:
|date=(help) - ↑ Karapetyan, YE.; Sferrazza, GF.; Zhou, M.; Ottenberg, G.; Spicer, T.; Chase, P.; Fallahi, M.; Hodder, P.; Weissmann, C. (2013). "Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents". Proc Natl Acad Sci U S A. 110 (17): 7044–9. doi:10.1073/pnas.1303510110. PMID 23576755. Unknown parameter
|month=ignored (help)